Case report: Invasive fungal infection in a patient with a rare CVID-causing gene (TNFRSF13B) mutation undergoing AML

Carine Tabak1, Stephen Hyter1, Abdulraheem Yacoub1

  • 1Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas School of Medicine, Kansas City, MO, United States.

Frontiers in Oncology
|April 3, 2023
PubMed

Insights

Acute myeloid leukemia (AML) patients face high infection risks. A case revealed a TNFRSF13B mutation linked to invasive fungal infections at AML diagnosis, highlighting the need for early immunodeficiency screening.

Area of Science:

  • Hematology
  • Infectious Diseases
  • Genetics

Background:

  • Acute myeloid leukemia (AML) increases susceptibility to infections, especially invasive fungal infections (IFI).
  • TNFRSF13B mutations are associated with B-cell dysfunction and immunodeficiency.
  • Early identification of immunodeficiency is crucial for managing AML patients.

Observation:

  • A male patient in his 40s diagnosed with AML presented with concurrent pulmonary and sinus mucormycosis.
  • Next-generation sequencing revealed a loss-of-function mutation in the TNFRSF13B gene.
  • The patient had invasive fungal infections at diagnosis, preceding neutropenia, suggesting an underlying immunodeficiency.

Findings:

  • The co-occurrence of AML and invasive fungal infections at diagnosis, without neutropenia, points to a potential immunodeficiency syndrome.
  • A TNFRSF13B mutation was identified as a contributing factor to the patient's compromised immune status.
  • This case underscores the complex interplay between malignancy, treatment, and immune function.

Implications:

  • Early detection of immunodeficiency syndromes in AML patients is critical for timely intervention.
  • Next-generation sequencing plays a vital role in identifying genetic risk factors for infections in cancer patients.
  • Managing concurrent infections and malignancies requires a careful, individualized treatment approach.